Clicky

Windtree Therapeutics, Inc(WINTW) News

Date Title
Jul 28 BNB Rises Over 6% Amid U.S.-EU Trade Deal and $610M Corporate Buying
Jul 26 BNB Rebounds to $780 After $520M Windtree Buy Commitment, Shows Signs of Stabilizing
Jul 25 Why Are Public Companies Amassing ETH, XRP, SOL, BNB Instead Of Just Bitcoin?
Jul 22 Kraken to Support Biotech Firm Windtree’s $200M BNB Treasury Play
Jun 26 Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel
May 6 Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
Feb 12 Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference
Oct 9 Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design
Jul 25 Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data
Dec 19 Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
Dec 18 Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
Aug 7 Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates